Correlation Between MediciNova and Cell Source
Can any of the company-specific risk be diversified away by investing in both MediciNova and Cell Source at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MediciNova and Cell Source into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between MediciNova and Cell Source, you can compare the effects of market volatilities on MediciNova and Cell Source and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MediciNova with a short position of Cell Source. Check out your portfolio center. Please also check ongoing floating volatility patterns of MediciNova and Cell Source.
Diversification Opportunities for MediciNova and Cell Source
0.14 | Correlation Coefficient |
Average diversification
The 3 months correlation between MediciNova and Cell is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding MediciNova and Cell Source in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cell Source and MediciNova is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MediciNova are associated (or correlated) with Cell Source. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cell Source has no effect on the direction of MediciNova i.e., MediciNova and Cell Source go up and down completely randomly.
Pair Corralation between MediciNova and Cell Source
Given the investment horizon of 90 days MediciNova is expected to generate 27.72 times less return on investment than Cell Source. But when comparing it to its historical volatility, MediciNova is 13.33 times less risky than Cell Source. It trades about 0.04 of its potential returns per unit of risk. Cell Source is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 39.00 in Cell Source on October 5, 2024 and sell it today you would lose (4.00) from holding Cell Source or give up 10.26% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 99.63% |
Values | Daily Returns |
MediciNova vs. Cell Source
Performance |
Timeline |
MediciNova |
Cell Source |
MediciNova and Cell Source Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with MediciNova and Cell Source
The main advantage of trading using opposite MediciNova and Cell Source positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MediciNova position performs unexpectedly, Cell Source can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cell Source will offset losses from the drop in Cell Source's long position.MediciNova vs. Aerovate Therapeutics | MediciNova vs. Adagene | MediciNova vs. Acrivon Therapeutics, Common | MediciNova vs. Rezolute |
Cell Source vs. Pasithea Therapeutics Corp | Cell Source vs. Nutriband Warrant | Cell Source vs. MediciNova | Cell Source vs. Virpax Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Complementary Tools
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |